GlaxoSmithKline, battered by weak US drug sales and a bribery scandal inChina, set out a bold recovery plan yesterday, including an initial public offering of part of its fast-growing HIV and AIDS drugs business.

GlaxoSmithKline’s difficult year continued today as shares tumbled on a warning that it no longer expects to improve a key measure of earnings.